Fischer Medical Ventures raises Rs 77.52 crore on warrants

Fischer Medical Ventures Limited allotted 4.417 crore equity shares through five warrant conversions in August 2026 and reported Rs 77.5184 crore of related proceeds for the half year ended September 30, 2026. The conversions, at Rs 23.40 per share, lifted paid-up capital by Rs 4.417 crore from March 31, 2026.

How many shares did Fischer Medical Ventures allot on warrant conversion?

Fischer Medical Ventures allotted 4.417 crore equity shares in five conversion events approved between August 11 and August 17, 2026. Every resulting share had a face value of Rs 1 and an issue price of Rs 23.40, including a premium of Rs 22.40 per share. The Board used circular resolutions dated August 11, 12, 13 and 14, followed by another circular resolution on August 17.

The August 14 conversion was the largest, producing 2.0505909 crore shares, followed by 1.4278217 crore shares on August 13. The remaining allotments were 66.31664 lakh shares on August 12, 23 lakh shares on August 11 and 4.5421 lakh shares on August 17. The August 13 and August 14 events together made up 3.4784126 crore shares, or most of the 4.417 crore shares issued in the five transactions.

The disclosed cash received was the balance exercise price of Rs 17.55 for each warrant, rather than the Rs 23.40 issue price of each resulting share. Fischer Medical Ventures received Rs 4.0365 crore on August 11, Rs 11.6385703 crore on August 12, Rs 25.058270835 crore on August 13, Rs 35.987870295 crore on August 14 and Rs 79.713855 lakh on August 17. The five disclosed payments total Rs 77.51834998 crore.

Who converted Fischer Medical Ventures warrants in August 2026?

Fischer Medical Ventures identified the warrant holders in the August 11, August 12 and August 17 allotments as belonging to the promoter category. These three events resulted in 93.85874 lakh shares, comprising 23 lakh, 66.31664 lakh and 4.5421 lakh shares respectively. Their disclosed balance exercise payments were Rs 4.0365 crore, Rs 11.6385703 crore and Rs 79.713855 lakh.

The August 13 and August 14 conversions involved persons in both promoter and non-promoter categories, according to the filing. These two allotments produced 3.4784126 crore shares and generated disclosed balance exercise cash of Rs 61.04614113 crore. The filing does not divide either the shares or payments between promoter and non-promoter warrant holders within those two mixed-category events.

Fischer Medical Ventures did not name the warrant holders, provide their post-conversion shareholdings or disclose the number of warrants still outstanding. It also did not disclose when the earlier portion of the Rs 23.40 issue price was paid. The stated Rs 17.55 payment on each conversion represents the balance exercise price received in August 2026.

How did the conversions change Fischer Medical Ventures share capital?

Fischer Medical Ventures reported paid-up equity share capital of Rs 69.8685 crore at September 30, 2026, compared with Rs 65.4515 crore at March 31, 2026. The Rs 4.417 crore increase equals the aggregate Rs 1 face value of the 4.417 crore shares allotted in August. The same September 30 paid-up capital figure appears in the standalone quarterly financial results.

The increase followed a 10-for-1 share subdivision that became effective on September 12, 2025. Under that action, each Rs 10 equity share was subdivided into 10 equity shares of Rs 1 each, after shareholder approval through a postal ballot on August 30, 2025. Fischer Medical Ventures said earnings per share for current and comparative periods were proportionately adjusted and restated for comparability.

Other equity stood at Rs 362.769 crore at September 30, 2026, up from Rs 272.6808 crore at March 31, 2026, while total equity rose to Rs 432.6376 crore from Rs 338.1323 crore. The filing does not allocate the Rs 90.0882 crore increase in other equity specifically between share premium, retained earnings or other components. Share capital therefore captures the face-value effect of the August issuances, not their entire cash effect.

What was the cash-flow effect of Fischer Medical Ventures warrant conversions?

Fischer Medical Ventures reported Rs 77.5184 crore of proceeds from issue of equity shares on conversion of warrants for the half year ended September 30, 2026. That compares with Rs 2.6145 crore in the half year ended September 30, 2025, an increase of Rs 74.9039 crore. The reported half-year cash-flow amount is consistent with the five August balance exercise payments, subject to rounding in the cash-flow statement.

Financing cash inflow of Rs 82.9275 crore included the warrant-conversion proceeds and Rs 11.4804 crore of net proceeds from long-term borrowings. It also included Rs 5.0743 crore of lease-liability repayments, Rs 94.87 lakh of interest and other finance costs paid, and Rs 4.82 lakh of dividends paid. The warrant proceeds were therefore the main disclosed financing inflow, but not the only movement in that section.

Cash and cash equivalents rose from Rs 1.1385 crore at the beginning of the half year to Rs 26.5178 crore at September 30, 2026. Operating activities used Rs 33.4451 crore, including Rs 28.9838 crore of higher other current assets, while investing activities used Rs 24.1031 crore, including Rs 26.6861 crore invested in subsidiaries. These outflows explain why the increase in closing cash was smaller than the reported financing inflow.

What was Fischer Medical Ventures financial position at September 2026?

Fischer Medical Ventures reported total assets of Rs 524.6269 crore at September 30, 2026, compared with Rs 388.6514 crore at March 31, 2026. Current assets increased to Rs 113.3302 crore from Rs 29.5792 crore, while cash and cash equivalents increased to Rs 26.5178 crore from Rs 1.1385 crore. Investments rose to Rs 356.0461 crore from Rs 303.5497 crore over the same period.

On a standalone basis, Fischer Medical Ventures reported total income of Rs 30.6534 crore for the quarter ended September 30, 2026, including Rs 30.3772 crore of other income and Rs 27.62 lakh of revenue from operations. Profit from continuing operations was Rs 20.5772 crore, compared with Rs 83.77 lakh in the September 2025 quarter. For the half year ended September 30, 2026, revenue from operations was Rs 99.79 lakh while other income was Rs 31.2678 crore.

Fischer Medical Ventures said it operates in one business segment under Indian Accounting Standard 108, Operating Segments, and therefore gave no separate segment disclosure. The audit committee reviewed the unaudited quarter and half-year results on November 14, 2026, and the Board approved them on the same date. The filing also says prior consolidated comparative figures were revised for audit adjustments at foreign subsidiaries, without affecting the Group's overall annual profit or closing reserves for the previous financial year.

Conclusion

The five August 2026 conversions added 4.417 crore shares and generated Rs 77.5184 crore of reported half-year proceeds from equity shares issued on warrant conversion. The August 13 and August 14 mixed promoter and non-promoter events accounted for 3.4784126 crore shares and Rs 61.04614113 crore of the disclosed balance exercise cash, making them the principal transactions in the issuance.

The next item to watch is whether Fischer Medical Ventures reports further warrant exercises, since the filing does not state the outstanding warrant balance, prospective conversion dates or holder-level allocations. Its next financial disclosures can also show how the September 30 cash balance of Rs 26.5178 crore changes after Rs 33.4451 crore of operating outflow and Rs 24.1031 crore of investing outflow in the reported half year.